Phase Ii | The Truth About Skin Care

{ Tag Archives } Phase Ii

Nitric BioTherapeutics Initiates Phase II Onychomycosis Study

Main Category: Infectious Diseases / Bacteria / Viruses
Also Included In: Dermatology; Clinical Trials / Drug Trials
Article Date: 16 Jul 2010 – 1:00 PDT

email to a friend printer friendly view / write opinions
<!– rate article

Nitric BioTherapeutics, Inc. (Nitric Bio) announced the initiation of a Phase II clinical trial of the [...]

Also tagged Biotherapeutics, Chairman Of The Board, Clinical Trial, Controlled Trial, Delivery System, Executive Chairman, Friendly View, Fungus, Industry Expert, Infectious Diseases, Interim Analysis, Iontophoresis, Onychomycosis, Oral Drug, Quaker Bioventures, Rate Article, Skin And Nails, Terbinafine, Treatment Option

2010 07 16 Skin Care News Comments Off

Morria Biopharmaceuticals Plc. Announces Initiation Of Its Phase II Study In Contact Dermatitis Patients Using MRX6, A Novel Anti-Inflammatory Drug

Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today the initiation of its Phase II clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX6. The double-blind, placebo-controlled study of up to 80 contact dermatitis patients will take place at the Hadassah Hospital in Israel…

Also tagged Anti Inflammatory Drugs, Biopharmaceutical Company, Biopharmaceuticals, Clinical Trial, Contact Dermatitis, Dermatitis, Double Blind Placebo, Hadassah Hospital, Inflammatory Drug, Initiation, Israel, Non Steroidal Anti Inflammatory Drugs, Plc

2010 04 23 Skin Care News Comments Off

PharmaSurgics To Extend Phase II Clinical Trial For Prevention Of Post-Surgical Adhesions

PharmaSurgics in Sweden AB – part of the Karolinska Development dermatology and wound healing company “Pergamum” has received approval from the Danish Medicines Agency and the Independent Ethics Committee to begin a phase II clinical trial in Denmark…

Also tagged Clinical Trial, Danish Medicines Agency, Denmark, Dermatology, Ethics Committee, Independent Ethics, Pergamum, Prevention, Sweden, Wound Healing

2010 04 13 Skin Care News Comments Off

Pharmasurgics To Begin Phase II Clinical Trial For Prevention Of Post-Surgical Adhesions

Pharmasurgics AB – part of the Karolinska Development dermatology and wound healing company “Pergamum” announced that Pharmasurgics has received approval from the Swedish Medical Products Agency to begin a Phase II clinical trial…

Also tagged Clinical Trial, Dermatology, Medical Products Agency, Pergamum, Prevention, Surgical Adhesions, Swedish Medical Products Agency, Wound Healing

2009 12 04 Skin Care News Comments Off

Sol-Gel’s IND Application For Rosacea Accepted By FDA

Sol-Gel Technologies announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Sol-Gel’s Investigational New Drug Application (IND) for DER45-EV Gel for the topical treatment of rosacea. This IND allows Sol-Gel to initiate Phase II studies with DER45-EV Gel in rosacea patients. DER45-EV Gel is an innovative topical product based [...]

Also tagged Drug Application, Drug Delivery System, Drugs, Efficacy, Fda, Food And Drug, Food And Drug Administration, Food And Drug Administration Fda, Receipt, Rosacea Patients, Sol Gel, Topical Treatment

2009 11 13 Skin Care News Comments Off

Novexel Starts Phase II Clinical Trial With NXL103 In Adults With Acute Bacterial Skin And Skin Structure Infections (ABSSSI)

Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI).

Also tagged Adults, Antibacterial, Bacterial Infections, Clinical Trial, Discovery, Global Problem, Microbial Resistance, Novel Antibiotics, Oral, Pharmaceutical Company, Skin And Skin, Skin Infections, Skin Structure Infections

2009 11 07 Skin Care News Comments Off

Can-Fite Initiates Preparatory Work For Psoriasis Phase III Trial With CF101

Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to [...]

Also tagged Aviv Stock, Biopharmaceutical Company, Biotechnology Company, Conclusion, Dose Response, Efficacy, Initiation, Objective, Phase Iii, Preparatory Work, Psoriasis, Tase, Tel Aviv Stock Exchange

2009 10 01 Skin Care News Comments Off

Morria Biopharmaceuticals Plc. Obtains Institutional Review Board Clearance To Conduct Phase II Study In Contact Dermatitis Patients Using MRX6

Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced that it has received written approval to commence its Phase II clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX6. The double-blind, placebo-controlled study on 80 contact dermatitis patients will take place at the Hadassah Hospital in Israel.

Also tagged Anti Inflammatory Drugs, Biopharmaceutical Company, Biopharmaceuticals, Clinical Trial, Contact Dermatitis, Dermatitis, Double Blind Placebo, Hadassah Hospital, Inflammatory Drug, Institutional Review Board, Israel, Non Steroidal Anti Inflammatory Drugs, Plc

2009 08 26 Skin Care News Comments Off

Thallion Suspends Patient Enrollment Of TLN-232 Metastatic Melanoma Trial Over Licensing Dispute

Thallion Pharmaceuticals Inc. (TSX:TLN) announced that it has suspended patient enrollment in its Phase II trial evaluating TLN-232 as a treatment for metastatic melanoma, due to an ongoing dispute with the licensor. A binding arbitration proceeding has been initiated and Thallion will re-evaluate the status of the program based on the outcome of the adjudication.

Also tagged Adjudication, Arbitration Proceeding, Binding Arbitration, Licensor, Melanoma, Metastatic Melanoma, Patient Enrollment, Pharmaceuticals Inc, Tln, Tsx

2009 07 08 Skin Care News Comments Off

Can-Fite-Completed Patient Enrollment For The Phase II Trial In Psoriasis With CF101

Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, has achieved yet another goal by completion of patients’ enrollment in its phase II Psoriasis trial. Approximately 70 patients were enrolled to this study, randomized into 4 groups treated with 1, 2 and 4 mg of CF101 and placebo. Patients are taking [...]

Also tagged Aviv Stock, Biotechnology Company, Europe, Groups, Israel, Patient Enrollment, Placebo Patients, Psoriasis, Randomized, Tase, Tel Aviv Stock Exchange

2009 06 02 Skin Care News Comments Off

The Truth About Skin Care

{ Tag Archives } Phase Ii

Nitric BioTherapeutics Initiates Phase II Onychomycosis Study

Morria Biopharmaceuticals Plc. Announces Initiation Of Its Phase II Study In Contact Dermatitis Patients Using MRX6, A Novel Anti-Inflammatory Drug

PharmaSurgics To Extend Phase II Clinical Trial For Prevention Of Post-Surgical Adhesions

Pharmasurgics To Begin Phase II Clinical Trial For Prevention Of Post-Surgical Adhesions

Sol-Gel’s IND Application For Rosacea Accepted By FDA

Novexel Starts Phase II Clinical Trial With NXL103 In Adults With Acute Bacterial Skin And Skin Structure Infections (ABSSSI)

Can-Fite Initiates Preparatory Work For Psoriasis Phase III Trial With CF101

Morria Biopharmaceuticals Plc. Obtains Institutional Review Board Clearance To Conduct Phase II Study In Contact Dermatitis Patients Using MRX6

Thallion Suspends Patient Enrollment Of TLN-232 Metastatic Melanoma Trial Over Licensing Dispute

Can-Fite-Completed Patient Enrollment For The Phase II Trial In Psoriasis With CF101

Home

Recommendations

Free Ebook

Latest News

Site Features

Get a free ebook valued at $8.95 when you sign up for our free Skincare Tips newsletter. The book The Truth About Skincare: How To Have Younger Looking Skin sells every day for $8.95 at Bargain Books Web. It's yours at no cost by immediate download when you sign up right now. You can unsubscribe any time, and the book is yours to keep.
Name:
Email: